EXPRESSION OF MIRNA-483-5P IN ESOPHAGEAL CANCER AND ITS CORRELATION WITH CLINICOPATHOLOGICAL FEATURES AND PROGNOSIS

Objective: To investigate the expression of miRNA-483-5p in esophageal cancer and its correlation with clinicopathological features and prognosis. Methods: This studys 82 cases of esophageal cancer tissue were archived at the study hospital between March 2013 and May 2014. In addition, 28 cases of paracancerous tissue were archived. Real-time fluorescent quantitative polymerase chain reaction was used to detect the relative expression levels of microRNA-483-5p (miRNA-483-5p) in esophageal cancer and adjacent tissues. The relative expression level of miRNA-483-5p was analysed with clinicopathological parameters and prognosis of patients with esophageal cancer. Results: The relative expression of miRNA-483-5p in esophageal cancer was (3.25 +/- 1.25), and the relative expression of miRNA-483-5p in adjacent tissue was (0.99 +/- 0.71). The difference was significant (P<0.05). The expression level of miRNA-483-5p was not related to the esophageal cancer patients gender, age, or histological grade, nor to the depth of invasion of the tissue (P>0.05). It was related to lymph node metastasis and the TNM stage of the esophageal cancer patient (P<0.05). The five-year survival rate of patients with relatively high levels of expression of miRNA-483-5p was 43.90% (18/41), and the five-year survival rate of patients with relatively low levels of expression of miRNA-483-5p was 75.61% (31/41). There was a significant difference (P<0.05). Results from the COX proportional hazard regression model showed that miRNA-483-5p expression level, lymph node metastasis, and TNM stage were independent prognostic factors for patients with esophageal cancer. Conclusions: The expression levels of miRNA-483-5p are elevated in esophageal cancer tissues, and its expression is related to lymph node metastasis and TNM staging in patients with esophageal cancer. MicroRNA-483-5p could be used as an independent risk factor in the prognoses of patients with esophageal cancer, being that it is of great significance in the onset and progression of esophageal cancer; it can be expected to become a new target for clinical treatment of esophageal cancer.